Literature DB >> 2164732

Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants.

B A Blacklaws1, S Krishna, A C Minson, A A Nash.   

Abstract

Vaccinia virus recombinants expressing glycoproteins B (vgB11), D (VgD52), E (gE/7.5 and gE/4B), G (gG-vac), H (gH-vac), and I (gI-vac) of HSV-1 were used to compare the protective response to these individual glycoproteins in the mouse. Glycoprotein D induced the best neutralizing antibody titers and the most increased rates of HSV clearance from the ear as well as good protection from the establishment of latent HSV infections in the sensory ganglia. Glycoprotein B also induced good neutralizing antibody titers and as great a protection from the establishment of latency as gD although the rate of virus clearance from the ear was not as great as after immunization with gD. Glycoprotein E induced weak neutralizing antibody but gG, gH, and gI did not show a neutralizing antibody response. At higher challenge doses of virus (10(6) PFU HSV-1 in the ear), gE induced a protective response by increasing the rate of virus clearance and reducing the acute infection of ganglia as compared to negative control immunized mice. However there was no protection from the establishment of latent infections after immunization with gE. No protective response was seen to gG, gH, or gl.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164732     DOI: 10.1016/0042-6822(90)90539-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.

Authors:  G R Skinner; C Fink; J Melling; C Wiblin; B Thornton; J Hallworth; W Gardner; P McLeish; C Hartley; A Buchan
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

2.  Expression of herpes simplex virus type 1 glycoprotein I in baculovirus: preliminary biochemical characterization and protection studies.

Authors:  H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Targeting vaccinia virus-expressed secretory beta subunit of human chorionic gonadotropin to the cell surface induces antibodies.

Authors:  J Srinivasan; O Singh; S Chakrabarti; G P Talwar
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

4.  The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.

Authors:  H Ghiasi; D C Roopenian; S Slanina; S Cai; A B Nesburn; S L Wechsler
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

5.  Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies.

Authors:  D E Goade; R Bell; T Yamada; G J Mertz; S Jenison
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

7.  A vaccinia virus--herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome the HSV type 2 induced humoral immunosuppression and protect against vaginal challenge in BALB/c mice.

Authors:  M Fleck; J Podlech; K Weise; D Falke
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

8.  Expression and characterisation of equine herpesvirus 1 glycoprotein H using a recombinant baculovirus.

Authors:  E M McGowan; M B Hayden; S J Edwards; D Pye; D N Love; J M Whalley
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1.

Authors:  M A Brehm; R H Bonneau; D M Knipe; S S Tevethia
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

10.  Expression of the Marek's disease virus (MDV) homolog of glycoprotein B of herpes simplex virus by a recombinant baculovirus and its identification as the B antigen (gp100, gp60, gp49) of MDV.

Authors:  M Niikura; Y Matsuura; D Endoh; M Onuma; T Mikami
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.